David Marmolejo
Overview
Explore the profile of David Marmolejo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, et al.
Cell Rep Med
. 2025 Feb;
6(2):101937.
PMID: 39914385
Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine clinical implementation of next-generation sequencing (NGS) is still limited. We...
2.
Talukder R, Bakaloudi D, Makrakis D, Diamantopoulos L, Enright T, Leary J, et al.
Clin Genitourin Cancer
. 2025 Jan;
23(1):102284.
PMID: 39798390
Background: FGFR2/3, MTAP and ERBB2 genomic alterations have treatment targets in advanced urothelial carcinoma (aUC). These alterations may affect tumor microenvironment and outcomes with immune checkpoint inhibitors (ICIs) in aUC....
3.
Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, et al.
Eur Urol
. 2024 Mar;
86(3):272-274.
PMID: 38490857
No abstract available.
4.
Hernando-Calvo A, Mirallas O, Marmolejo D, Saavedra O, Vieito M, Assaf Pastrana J, et al.
Oral Oncol
. 2023 Mar;
140:106364.
PMID: 36989964
Background: Beyond programmed death-ligand 1 (PD-L1) assessed by the combined positive score (CPS) and tumor mutational burden (TMB), no other biomarkers are approved for immunotherapy interventions. Here, we investigated whether...
5.
Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, et al.
Front Oncol
. 2022 Oct;
12:970199.
PMID: 36267983
Collecting duct renal cell carcinoma (cdRCC), which until recently was thought to arise from the collecting ducts of Bellini in the renal medulla, is a rare and aggressive type of...
6.
Villacampa G, Hernando-Calvo A, Berche R, Saavedra O, Marmolejo D, Mirallas O, et al.
Cancer Treat Rev
. 2022 Oct;
111:102465.
PMID: 36209603
No abstract available.
7.
Cedres S, Assaf J, Iranzo P, Callejo A, Pardo N, Navarro A, et al.
Sci Rep
. 2021 Nov;
11(1):21357.
PMID: 34725384
CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is...
8.
Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34209601
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Unfortunately, only some patients benefit from these therapies. Thus, certain clinicopathological characteristics of the patients have been proposed...
9.
Saoudi Gonzalez N, Salva F, Ros J, Baraibar I, Marmolejo D, Valdivia A, et al.
Expert Opin Biol Ther
. 2021 Jun;
21(10):1315-1324.
PMID: 34085884
: Colorectal cancer (CRC) is a major public health problem. Despite major progress understanding the biological basis of this tumor added to the incorporation of optimized diagnostic and therapeutic strategies,...
10.
Riveiro-Barciela M, Gonzalez-Sans D, Marmolejo D, Salcedo M, Munoz-Couselo E
J Gastrointestin Liver Dis
. 2021 Mar;
30(1):171-172.
PMID: 33723557
No abstract available.